Status:
COMPLETED
Plan D- Vitamin D Supplementation in Psychotic Disorders
Lead Sponsor:
University Hospital, Akershus
Collaborating Sponsors:
University of Oslo
Oslo University Hospital
Conditions:
Schizophrenia Spectrum and Other Psychotic Disorders
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
Background: Impairment in cognitive processing speed is a consistent finding in schizophrenia spectrum disorder. Vitamin D deficiency is found to be significantly associated with reduced processing sp...
Detailed Description
Background: Vitamin D deficiency is considered a risk factor for schizophrenia spectrum disorders. The influence from vitamin D may be specifically important in the developing fetal brain. However, v...
Eligibility Criteria
Inclusion
- a diagnosis of schizophrenia, schizoaffective disorder, schizophreniform disorder, schizophreniform disorder or psychotic disorder not otherwise specified
- ability to give informed consent
- S-25(OH)D\< 75nmol/L
Exclusion
- psychotic symptoms with organic etiology
- severe mental retardation (IQ\<70)
- hyperparathyroidism
- hypercalcemia
- renal failure (s-creatinine levels above 90µmol/L in women and above 105µmol/L for men)
- pregnancy
Key Trial Info
Start Date :
April 4 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2025
Estimated Enrollment :
14 Patients enrolled
Trial Details
Trial ID
NCT05211635
Start Date
April 4 2022
End Date
January 1 2025
Last Update
January 29 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Akershus University Hospital, Division of Psychiatry
Lørenskog, Norway, 1478